Jason V. Coloma
CEO & DirectorDr. Jason V. Coloma, Ph.D., M.P.H., MBA, is Director and CFO of Ollin Biosciences Inc. He had been Director of Braveheart Bio, Inc. since May 2024 until July 2026. He serves as the Chief Executive Officer and Director of Maze Therapeutics, Inc. since July 2019 and served as its President, Chief Mazer and Chief Operating Officer until May 2023. He had been an Independent Director at BioAge Labs, Inc. since August 2021 until August 20, 2024. Dr. Coloma served as Chief Business Officer of Celsius Therapeutics, Inc. until November 2018. Before he became CEO, he was Maze’s interim COO and a venture partner at Third Rock Ventures from June 2016 to July 2019. He served as Venture Partner at Third Rock Ventures, LLC. He joined Third Rock in 2017. Dr. Coloma served as Chief Business Officer and Senior Vice President of Corvus Pharmaceuticals, Inc. from June 08, 2016 to December 2017. Dr. Coloma began his career as a research scientist in infectious diseases at the University of California (UCSF). In 2007, he joined L.E.K. Consulting, as a strategy consultant in the life science for pharma / biotechnology corporations and private equity firms developing partnerships, mergers & acquisitions and market expansion opportunities primarily in the oncology market for his clients and focused on business development and corporate strategy for biopharma clients. From August 2007 and July 2016, he held a number of roles at Roche, including, Global Head of Research Technology Partnering, Vice President & global therapeutic area head of oncology and cancer immunotherapy partnering. For the last several years, Dr. Coloma has worked in senior leadership positions related to business and commercial development at Roche Diagnostics and then Roche/Genentech. He served as VP and global therapeutic area head of oncology immunotherapy partnering at Roche. Most recently, he led a team of business development professionals, business analysts and competitive intelligence experts charged with augmenting Roche's drug discovery and oncology business efforts where he led or oversaw numerous transactions ranging from research collaborations to mergers and acquisitions and he facilitated the closing of a number of deals including partnerships with Third Rock portfolio companies Foundation Medicine and Blueprint Medicines and also involved in sQz Therapeutics, Tensha Therapeutics, C4 Therapeutics and Pieris Pharmaceuticals. He also oversaw the creation of the immuno-oncology clinical partnership function at Genentech that completed several transactions including those with Celgene, J&J, Bayer, Syndax, Kite, Amgen and Corvus Pharmaceuticals. He also worked in finance at Amgen and in research at the University of Califormia. Dr. Coloma has been Director of Alloy Therapeutics, Inc. since November 2018. He is a member of the boards of the St. Anthony Foundation. Dr. Coloma received his M.P.H./Ph.D. in Infectious Diseases and Immunity from the University of California, Berkeley and his M.B.A. from the Tuck School of Business at Dartmouth from 2005 to 2007. Dr. Coloma earned his B.S. in Biology from the University of San Francisco.
Positions
- Company NameMaze Therapeutics, Inc.Stock CodeMAZEPositionCEO & DirectorColleagues
- HHHerve HoppenotChairman of the Board
- MTMisbah TahirCFO & Principal Accounting Officer
- HSHarold S. BernsteinPresident of Research & Development and Chief Medical Officer
- VVVipin VijayakumarSenior Vice President of Technology and Business Operations
- MHMaarten HoekChief Scientific Officer
- DKDaniel K. SpiegelmanIndependent Non-Employee Director
- JEJonathan E. LimIndependent Non-Employee Director
- CJCharles J. HomcyDirector
